87 related articles for article (PubMed ID: 2942018)
1. [Phase I study with LH-RH agonist, ICI 118630].
Usami M; Kotake T; Sonoda T
Hinyokika Kiyo; 1986 Mar; 32(3):493-501. PubMed ID: 2942018
[TBL] [Abstract][Full Text] [Related]
2. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
[TBL] [Abstract][Full Text] [Related]
3. Influence of LH-RH agonists on the growth and hormonal environment of breast and prostate cancer.
Nicholson RI; Walker KJ
Chemioterapia; 1985 Jun; 4(3):249-51. PubMed ID: 3161643
[TBL] [Abstract][Full Text] [Related]
4. Intermittent long-term administration of a potent gonadotropin-releasing hormone agonist in normal men.
Doelle G; Linde R; Alexander N; Kirchner F; Vale W; Rivier J; Rabin D
Int J Fertil; 1982; 27(4):234-7. PubMed ID: 6131043
[TBL] [Abstract][Full Text] [Related]
5. Comparison of mammalian luteinizing hormone releasing hormone (LH-RH), and of an analog (ICI 118630), on luteinizing hormone and ovarian steroid (progesterone, oestradiol) secretions in laying hens. (Gallus domesticus).
Guémené D; Williams JB
Life Sci; 1986 Aug; 39(6):541-7. PubMed ID: 2942749
[TBL] [Abstract][Full Text] [Related]
6. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
Williams MR; Walker KJ; Turkes A; Blamey RW; Nicholson RI
Br J Cancer; 1986 May; 53(5):629-36. PubMed ID: 2941044
[TBL] [Abstract][Full Text] [Related]
7. Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men.
Nillius SJ; Bergquist C; Wide L
Int J Fertil; 1980; 25(3):239-46. PubMed ID: 6108935
[TBL] [Abstract][Full Text] [Related]
8. [A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies].
Tsukagoshi S
Gan To Kagaku Ryoho; 2002 Sep; 29(9):1675-87. PubMed ID: 12355959
[TBL] [Abstract][Full Text] [Related]
9. The effect of injection and infusion of LH-RH on serum LH and FSH in normal males and in boys with delayed puberty.
De Lange WE; Sluiter WJ; Van Zanten AK; Doorenbos H
Neth J Med; 1974; 17(4-5):196-201. PubMed ID: 4619183
[No Abstract] [Full Text] [Related]
10. [Endocrine therapy for prostatic carcinoma--the clinical trial to compare the efficacy of LH-RH analogue, ICI 118630 (Zoladex) with castration or estrogen].
Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Akaza H; Niijima T; Aso Y; Araki T; Itatani H
Hinyokika Kiyo; 1988 Oct; 34(10):1853-63. PubMed ID: 2977527
[TBL] [Abstract][Full Text] [Related]
11. Effect of Lh-Rh on antibody formation, sperm count and plasma levels of gonadotropins and testosterone in normal men.
Stone SC; Jaramillo F; Kastin AJ; Arimura A; Vargas JR; Schally AV; Dickey RP
Int J Fertil; 1974; 19(4):192-6. PubMed ID: 4376533
[TBL] [Abstract][Full Text] [Related]
12. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
[No Abstract] [Full Text] [Related]
13. Effects of a single injection of a new depot formulation of an LH-releasing hormone agonist on spermatogenesis in adult rats.
van Kroonenburgh MJ; Beck JL; Vemer HM; Rolland R; Thomas CM; Herman CJ
J Endocrinol; 1986 Dec; 111(3):449-54. PubMed ID: 2949040
[TBL] [Abstract][Full Text] [Related]
14. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
[TBL] [Abstract][Full Text] [Related]
15. Effects of a gonadotropin-releasing hormone agonist analog (ICI 118630) on endocrine functions of human testis in vivo and in vitro.
Namiki M; Nonomura N; Nakamura M; Okuyama A; Sonoda T; Nishimune Y; Matsumoto K
Fertil Steril; 1987 Dec; 48(6):1012-7. PubMed ID: 2960563
[TBL] [Abstract][Full Text] [Related]
16. Serum FSH and LH levels in men after administration of a long-acting LH-RH preparation.
Laczi F; Julesz J; Bártfai G; Sas M; László FA
Acta Med Acad Sci Hung; 1982; 39(3-4):125-31. PubMed ID: 6821016
[TBL] [Abstract][Full Text] [Related]
17. Gonadotropin release after administration of LH-RH during early follicular phase.
Hanker JP; Ende U; Bohnet HG; Schneider HP
Int J Fertil; 1980; 25(2):100-5. PubMed ID: 6117522
[TBL] [Abstract][Full Text] [Related]
18. Suppression of ovarian activity by Zoladex depot (ICI 118630), a long-acting luteinizing hormone releasing hormone agonist analogue.
West CP; Baird DT
Clin Endocrinol (Oxf); 1987 Feb; 26(2):213-20. PubMed ID: 2959405
[TBL] [Abstract][Full Text] [Related]
19. Pituitary response to luteinizing hormone-releasing hormone analog at sea level and high altitudes.
Paredes Suarez M; Varea Teran JR; Garces G; Avila C; Coy DH; Schally AV
Obstet Gynecol; 1982 Jan; 59(1):52-7. PubMed ID: 6804897
[TBL] [Abstract][Full Text] [Related]
20. Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue.
Mahler C; Verhelst J; Chaban M; Denis L
Cancer; 1991 Feb; 67(3):557-9. PubMed ID: 1824680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
